AMRN in the last 3-4 months has accomplished all of the following..
- Launched Vascepa on time as advertised
- 4 New Patents
- sNDA ANCHOR submitted for PDUFA date this year
- Tier 2 coverage, unheard of for drug at this stage.
- 1st ever ANCHOR Patent 520
And over the next 45 days AMRN has these catalysts..
- ANCHOR PDUFA
- Combo-Statin Data
- 2 more Patents
- Q1 Script data 100% and guidance ahead
These are the REAL (negative) catalysts going forward (written by someone whi has been right about AMRN):
*Script and sales numbers will be very bad ("declining acceleration" from a very low base)
*Street estimates are WAY too high and both sales and PPS estimates will be cut with at least 60 to 80% very soon going forward.
*PPS will soon be under $5 and that will really start instituitional sell offs combined with heavy short attacks and probably forced selling of retail suc*ers.
*The fear of leveraged AMRN going bankrupt very soon will be very real
*This will guarantee a veritable death spiral (the lower the PPS the larger the fear, the lower the PPS the higher the dilution and so on)
*Mgt will probably leave very soon when they understand that they won't be able to pump Anchor, there are NO upside for them in staying with a sinking ship, ONLY upside (ESPECIALLY if they can dump their remaining holdings before AMRN is at penny levels).